MX360030B - Metodos para tratar el trastorno bipolar. - Google Patents

Metodos para tratar el trastorno bipolar.

Info

Publication number
MX360030B
MX360030B MX2016002438A MX2016002438A MX360030B MX 360030 B MX360030 B MX 360030B MX 2016002438 A MX2016002438 A MX 2016002438A MX 2016002438 A MX2016002438 A MX 2016002438A MX 360030 B MX360030 B MX 360030B
Authority
MX
Mexico
Prior art keywords
bipolar disorder
methods
treating bipolar
treating
amide
Prior art date
Application number
MX2016002438A
Other languages
English (en)
Spanish (es)
Inventor
James Lee Sung
Marie Melnick Susan
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of MX360030B publication Critical patent/MX360030B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2016002438A 2010-06-30 2011-06-27 Metodos para tratar el trastorno bipolar. MX360030B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/827,505 US9610274B2 (en) 2010-06-30 2010-06-30 Methods for treating bipolar disorder
PCT/KR2011/004676 WO2012002687A2 (en) 2010-06-30 2011-06-27 Methods for treating bipolar disorder

Publications (1)

Publication Number Publication Date
MX360030B true MX360030B (es) 2018-10-19

Family

ID=45400168

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012014686A MX2012014686A (es) 2010-06-30 2011-06-27 Metodos para tratar el transtorno bipolar.
MX2016002438A MX360030B (es) 2010-06-30 2011-06-27 Metodos para tratar el trastorno bipolar.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012014686A MX2012014686A (es) 2010-06-30 2011-06-27 Metodos para tratar el transtorno bipolar.

Country Status (13)

Country Link
US (2) US9610274B2 (zh)
EP (1) EP2590645B1 (zh)
JP (1) JP5881692B2 (zh)
KR (1) KR101828934B1 (zh)
CN (1) CN102985085B (zh)
AU (1) AU2011272156B2 (zh)
BR (1) BR112012033738A2 (zh)
CA (1) CA2801241C (zh)
ES (1) ES2654615T3 (zh)
MX (2) MX2012014686A (zh)
PL (1) PL2590645T3 (zh)
RU (1) RU2653408C2 (zh)
WO (1) WO2012002687A2 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201328689A (zh) 2005-06-08 2013-07-16 Sk Biopharmaceuticals Co Ltd 治療睡眠-覺醒病症之方法
BRPI1015233A2 (pt) 2009-06-22 2018-02-20 Sk Biopharmaceuticals Co Ltd métodos para tratar ou prevenir a fadiga
CA2905457A1 (en) 2013-03-13 2014-10-09 Aerial Biopharma, Llc Treatment of cataplexy
PT3021838T (pt) 2013-07-18 2020-09-01 Sk Biopharmaceuticals Co Ltd Tratamento para a obesidade
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
TWI698415B (zh) 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
CA3036071A1 (en) 2016-09-06 2018-03-15 Jazz Pharmaceuticals International Iii Limited Solvate form of (r)-2-amino-3-phenylpropyl carbamate
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
WO2018067971A1 (en) 2016-10-06 2018-04-12 Jazz Pharmaceuticals International Iii Limited Carbamoyl phenylalaninol compounds and uses therof
EP3556366A4 (en) * 2016-12-14 2020-06-17 SK Biopharmaceuticals Co., Ltd. USE OF CARBAMATE COMPOUNDS FOR THE PREVENTION, MITIGATION OR TREATMENT OF BIPOLAR DISORDER
KR20200016889A (ko) 2017-06-02 2020-02-17 재즈 파마슈티칼즈 아일랜드 리미티드 과다 졸림증을 치료하기 위한 방법 및 조성물
KR102643275B1 (ko) 2017-07-31 2024-03-04 재즈 파마슈티칼즈 아일랜드 리미티드 카바모일 페닐알라니놀 유사체 및 이의 용도
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109872A (en) 1993-06-10 2000-12-06 Lilly Co Eli Tetrahydrobenz ¬CD¾ indole-6-carboxamides for use in preventing emesis and pharmaceutical compositions comprising same
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
IT1275903B1 (it) 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
CA2240060C (en) 1996-10-10 2007-07-17 Sk Corporation O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same
AU4674797A (en) 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
TW548103B (en) 1997-07-11 2003-08-21 Janssen Pharmaceutica Nv Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
CA2330475A1 (en) 1998-04-28 1999-11-04 Dainippon Pharmaceutical Co., Ltd. 1-¬(1-substituted-4-piperidinyl)methyl|-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
US20010029262A1 (en) 1998-06-29 2001-10-11 Sethi Kapil Dev Method of treatment or prophylaxis
TW518218B (en) 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
US20010034320A1 (en) 2000-01-18 2001-10-25 Hans-Michael Brecht NK1-receptor antagonists for treating restless legs syndrome
WO2002050071A1 (en) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
US6815464B2 (en) 2001-02-27 2004-11-09 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in the treatment of pain
HUP0303344A3 (en) 2001-02-27 2012-07-30 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing and treating movement disorders
CA2443108A1 (en) 2001-04-03 2002-10-17 Merck & Co. Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
US20040204341A1 (en) 2001-06-12 2004-10-14 Christopher Allen Nr2b receptor antagonists for the treatment or prevention of migraines
US20040115263A1 (en) 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
MXPA05003065A (es) 2002-09-20 2005-05-27 Pfizer Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht4.
WO2004094418A1 (en) 2003-04-21 2004-11-04 Pfizer Inc. Imidazopyridine compounds having 5-ht4 receptor agonistic activity and 5-ht3 receptor antagonistic activity
AP2184A (en) 2003-09-03 2010-12-02 Pfizer Benzimidazolone compounds having 5-HT4 receptor agonistic activity.
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
EP1548011A1 (en) 2003-12-23 2005-06-29 Neuro3D Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof
WO2005092882A1 (en) 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
RU2007119648A (ru) * 2004-10-28 2008-12-10 СК Холдингз Ко. Способ лечения депрессии
CN101189228A (zh) 2005-04-08 2008-05-28 辉瑞产品有限公司 用作i型甘氨酸转运抑制剂的二环[3.1.0]杂芳酰胺
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
TW201328689A (zh) 2005-06-08 2013-07-16 Sk Biopharmaceuticals Co Ltd 治療睡眠-覺醒病症之方法
US8552060B2 (en) 2005-06-22 2013-10-08 Sk Biopharmaceuticals Co., Ltd. Methods for treatment of sexual dysfunction
CA2616721C (en) 2005-07-26 2014-01-21 Janssen Pharmaceutica N.V. Methods for treating substance-related disorders
EP1754476A1 (en) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
WO2008048801A2 (en) 2006-10-13 2008-04-24 Janssen Pharmaceutica Nv Phenylalkylamino carbamate compositions
HUP0700370A2 (en) * 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment of acute mania
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
BRPI1015233A2 (pt) 2009-06-22 2018-02-20 Sk Biopharmaceuticals Co Ltd métodos para tratar ou prevenir a fadiga
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
KR101097605B1 (ko) 2009-11-04 2011-12-22 알.에프 에이치아이씨 주식회사 도허티 증폭기
CA2779457C (en) 2009-11-06 2017-10-17 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
CA2779442A1 (en) 2009-11-06 2011-05-12 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome

Also Published As

Publication number Publication date
US20120004300A1 (en) 2012-01-05
WO2012002687A2 (en) 2012-01-05
EP2590645A4 (en) 2014-01-22
JP5881692B2 (ja) 2016-03-09
CN102985085B (zh) 2018-10-02
ES2654615T3 (es) 2018-02-14
AU2011272156A1 (en) 2013-02-07
JP2013533253A (ja) 2013-08-22
PL2590645T3 (pl) 2018-03-30
CA2801241A1 (en) 2012-01-05
EP2590645A2 (en) 2013-05-15
MX2012014686A (es) 2013-02-11
AU2011272156B2 (en) 2015-02-12
EP2590645B1 (en) 2017-10-04
CA2801241C (en) 2018-07-17
CN102985085A (zh) 2013-03-20
US9907777B2 (en) 2018-03-06
KR101828934B1 (ko) 2018-03-29
US9610274B2 (en) 2017-04-04
US20170151209A1 (en) 2017-06-01
RU2012155118A (ru) 2014-08-10
WO2012002687A3 (en) 2012-04-26
BR112012033738A2 (pt) 2017-08-08
RU2653408C2 (ru) 2018-05-08
KR20130112706A (ko) 2013-10-14

Similar Documents

Publication Publication Date Title
MX360030B (es) Metodos para tratar el trastorno bipolar.
EP2588099A4 (en) METHOD OF TREATING THE RESTLESS LEG SYNDROME
MX350745B (es) El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
PH12015500719A1 (en) Gdf-8-inhibitors
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
PH12014501695A1 (en) Pde9 inhibitors with imidazo triazinone backbone
EA201290859A1 (ru) Лечение люпус-артрита с использованием лаквинимода
MY183582A (en) Deuterated cftr potentiators
MX349159B (es) Derivados deuterados de ivacaftor.
IN2014KN00948A (zh)
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
MY170922A (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
EA201490269A1 (ru) Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета
MX2013012588A (es) Inhibidores de cinasa.
CA2881554C (en) Methods for inhibiting fascin
MX2012013740A (es) Metodos para tratar trastornos resistentes al metotrexato con 10-propargil-10-deaza-aminopterina.
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
PH12014500990A1 (en) Methods for treating gout flares
MX2015008187A (es) Inhibidores de alk deuterados.
EA201690327A1 (ru) Терапевтические способы
PH12014502065A1 (en) Vesicular formulations
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
MX2018001684A (es) Metodo de curacion de heridas.